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Introduction: Platelet activation, thrombin generation and fibrin formation play important roles in intracoronary
thrombus formation, which may lead to acute myocardial infarction.
We investigated whether the prothrombotic markers D-dimer, pro-thrombin fragment 1 + 2 (F1 + 2) and endogenous
thrombin potential (ETP) are associated with myocardial necrosis assessed by Troponin T (TnT), and left ventricular
impairment assessed by left ventricular ejection fraction (LVEF) and N-terminal pro b-type natriuretic peptide
(NT-proBNP).
Materials/Methods: Patients (n = 987) with ST-elevation mycardial infarction (STEMI) were included. Blood
samples were drawn at a median time of 24 h after onset of symptoms.
Results: Statistically significant correlations were found between both peak TnT and D-dimer (p < 0.001) and F1 + 2
(p < 0.001), and between NT-proBNP and D-dimer (p = 0.001) and F1 + 2 (p < 0.001). When dividing TnT and NT-proBNP
levels into quartiles there were significant trends for increased levels of both markers across quartiles (all p < 0.001)
D-dimer remained significantly associated with NT-proBNP after adjustments for covariates (p = 0.001) whereas the
association between NTproBNP and F1 + 2 was no longer statistically significant (p = 0.324).
A significant inverse correlation was found between LVEF and D-dimer (p < 0.001) and F1 + 2 (p = 0.013). When
dichotomizing LVEF levels at 40 %, we observed significantly higher levels of both D-dimer (p < 0.001) and F1 + 2
(p = 0.016) in the group with low EF (n = 147).
Summary/conclusion: In our cohort of STEMI patients we demonstrated that levels of D-dimer and F1 + 2 were
significantly associated with myocardial necrosis as assessed by peak TnT. High levels of these coagulation
markers in patients with low LVEF and high NTproBNP may indicate a hypercoagulable state in patients with
impaired myocardial function.
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Coronary artery disease (CAD) is a progressive athero-
sclerotic condition and is, together with thrombus for-
mation, the most important underlying mechanism of an
acute myocardial infarction (AMI) [1–4].
In addition to platelet activation, thrombin generation
and fibrin formation play an important role in the devel-
opment of an intracoronary thrombus, which may lead
to an acute coronary occlusion [2, 5, 6].
The generation of thrombin through the tissue factor
pathway is essential in the haemostatic process [1, 2, 7].
It is crucial in normal physiology, whereas an inappro-
priate generation of thrombin may contribute to vascular
occlusions such as in myocardial infarction. Increased
thrombin generation, as an expression of activation of
the coagulation system, was previously shown in patients
with acute coronary syndrome and unstable angina pec-
toris [8, 9].
When prothrombin is converted to activated throm-
bin, prothrombin fragment 1 + 2 (F1 + 2) is formed, thus
indicating thrombin generation in vivo, with subsequent
fibrin formation. From the fibrinolytic system, plasmin
converted from plasminogen degrades fibrin, resulting in
degredation products like D-dimer. Elevated D-dimer
levels therefore indicate both ongoing coagulation and
fibrinolytic activation. Both markers have been shown to
be persistantly elevated for months after the acute
myocardial infarction [5], whereas an early decrease in
D-dimer levels has been shown to be associated with
improved prognosis [10].
The endogenous thrombin potential (ETP) has been
proposed as an informative method to determine the de-
gree of hypercoagulability, measuring the potential to
generate thrombin ex vivo [11].
Several studies have shown increased levels of pro-
thrombotic markers in patients with myocardial infarc-
tion [10, 12] and also association to clinical outcome
[10, 13, 14]. There is, however, limited knowledge about
activation of the coagulation cascade in the acute phase
of ST-elevation myocardial infarction (STEMI) and also
limited data on the degree of hypercoagulability in rela-
tion to the degree of myocardial injury and severity of
the disease in these patients.
The aim of the present substudy was therefore to
investigate whether circulating levels of selected pro-
thrombotic markers were associated with the degree
of myocardial necrosis assessed by peak troponin T
(TnT) and with left ventricular impairment assessed
by left ventricular ejection fraction (LVEF) and N-
terminal pro b-type natriuretic peptide (NT-proBNP)
in STEMI patients. Furthermore, the degree of hyper-
coagulability was studied in relation to traditional risk
factors and baseline characteristics of the STEMI
population.Material and methods
A total of 987 percutaneous coronary intervention
(PCI)-treated STEMI patients from a cross sectional co-
hort study were included, all admitted to Oslo University
Hospital Ullevål, Oslo, Norway in the period from June
2007 to August 2011. STEMI was defined as ST segment
elevation of >2 mm in two or more contiguous chest
leads or > 1 mm in two or more limb leads or left bundle
branch block, together with typical chest pain and ele-
vated troponin levels above the recommended diagnostic
threshold. Patients on warfarin treatment, below 18 years
of age and patients unable or unwilling to give written
informed consent were excluded. Blood samples were
collected at median time of 24 h after symptoms and
18 h after the PCI procedure, between 8 and 10 a.m. the
following morning. In order to standardize blood sam-
pling, and also to avoid any influence of diurnal varia-
tions and food intake, all samples were taken after an
overnight fast. Routine blood samples were drawn at
hospital admission, and samples for TnT were measured
after standardized time intervals.
Citrated blood (0.129 M trisodium citrate in dilution
1:10) was centrifuged within 30 min at 2500 × g at 4 °C
and kept frozen at ÷80 °C until analyzed. D-dimer and
F1 + 2 were determined by ELISA (Asserachrom D-
dimer, Stago Diagnostica, Ansiere, France and Enzygnost
F1 + 2, Siemens, Marburg, Germany, respectively). Coeffi-
cients of variation (CV) were for D-dimer 6.5 % and F1+ 2
5.4 %.
ETP was determined by the Calibrated Automated
Thrombogram (CAT) assay according to the manufac-
turer’s instructions (Thrombinoscope BV, Maastricht,
The Netherlands) and thrombin generation was mea-
sured on the Fluoroscan Ascent fluorometer (Thermo
Fisher Scientific OY, Vantaa, Finland). A reagent mixture
of rTF and phospholipids in addition to a thrombin-
specific fluorogenic substrate in Hepes buffer containing
CaCl2 was added to the plasma to obtain a final concen-
tration of 5 pM, 4 μM and 416.7 μM, respectively. In
order to calculate the final results, plasma was measured
along with a thrombin calibrator. The software (version
3.0.0.29; Thrombinoscope BV) enabled the calculation of
the lag time (LT), peak thrombin generation (pTG), ETP
and time to peak (TTP). Further, VT (Velocity Index) =
TP/(TTP-LT), indicating the average net rate of pro-
thrombin activation during the propagation phase, was
calculated. All experiments were run in duplicates and the
interassay coefficients of variation for the different CAT
parameters were 14.2, 4.6, 5.0 and 8.0 %, respectively.
CRP was measured with kits from DRG Instruments
(Marburg/Lahn, Germany), CV <5 %.
Electrochemiluminescence technology for quantitative
measurement was used for repeated measures of TnT (3rd
generation cTroponinT, Elecsys 2010, Roche, Mannheim,
Table 1 Characteristics of the study population (n = 987)
Age (years) (range) 61 (24–94)
Male sex 800 (81)
Current smokers 474 (48)
Previous CVD 229 (23)
Treated hypertension 334 (34)
Treated diabetes mellitus 124 (12)
BMI (kg/m2) 26.6 (24.3,29.2)
Prehospital thrombolysis 119 (12)
Aspirin 231 (23)
Statins 233 (23)
Total cholesterol (mmol/L) 4.9 (4.1,5.6)
HDL (mmol/L) 1.06 (0.88,1.30)
Triglycerides (mmol/L) 1.25 (0.89,1.78)
CRP (mg/L) 13.4 (7.0,31.3)
Admission glucose (mmol/L) 7.4 (6.3,9.0)
Fasting glucose (mmol/L) 5.8 (5.2,6.6)
HbA1c (%) 5.9 (5.6,6.3)
Peak Troponin T (ng/L) 3850 (1710,7250)
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L with a recommended diagnostics threshold of 30 ng/L.
The inter-assay coefficient of variation was 7 %. NT-
ProBNP was measured in serum using Elecsys proBNP
sandwich immunoassay on Elecsys 2010 (Roche Diagnos-
tics, Indianapolis, USA). The inter-assay coefficient of vari-
ation was 7 %.
Left ventricular ejection fraction (LVEF) was mea-
sured by echocardiography before hospital discharge or
at a clinical follow-up within 3 months after the AMI
(n = 767).
Diabetes was defined according to the American Dia-
betes Association criteria [15] and hypertension (HT)
was defined as previously diagnosed and treated hyper-
tension. Smokers were defined as current smokers or
quit within the last month.
Clinical information was collected from hospital re-
cords and questionnaires acquired at the time of inclu-
sion. Patients on warfarin were not included in this
patient cohort.
The study was approved by The Regional Ethics Com-
mitee and all patients gave written informed consent.
NT-ProBNP (pmol/L) 31 (10,118)
LV Ejection fraction (%) 50 (44,55)
D-dimer (ng/mL) 456 (287,796)
F1 + 2 (pmol/L) 246 (178,356)
ETP (nM⋅min) 1564 (1366,1743)
Time from onset of symptoms to blood
sampling (hours) (range)
24 (5–118)
Number (proportions) or median (25,75 percentiles) are given
BMI Body mass index, CVD Cardiovascular Disease, HDL High Density
lipoprotein cholesterol, CRP C-reactive Protein, ETP endogenous thrombin
potentialStatistical analysis
Continous variables are presented as median values with
25,75 percentiles and categorial variables as number or
proportions. As most of the variables were skewed,
correlation analyses were performed using Spearman’s
method. Differences between groups were tested by
Mann–Whitney U test for continuous variables. Associa-
tions between prothrombotic markers and peak TnT and
left ventricular impairment were tested in multivariate
regression models, adjusting for relevant covariates. As
the markers are strongly inter-related they were analyzed
in separate models. Skewed data were log-transfomed
before entered in the model. P values < 0.05 were consid-
ered statistically significant. The statistical analyses were
performed with SPSS software version 18.0 (SPSS Inc,
Chicago, USA).Results
Baseline characteristics of the total population are given
in Table 1. The cohort was a typical STEMI population
of relatively young, predominantly male patients (81 %)
with medium size infarction (measured by peak TnT).
Only 23 % with previous CVD, 12 % with known dia-
betes and half of the patients were smokers.
Levels of the haemostatic variables in the total popula-
tion are shown in Table 1.
There were strong inter-correlations between D-dimer
and F1 + 2 (r = 0.504, p < 0.001), and a weaker, inverse
correlation between D-dimer and ETP (r = −0-.102, p <
0.001).As visualized in Table 2, age was significantly corre-
lated with F1 + 2 and D-dimer, inversely to ETP (all p <
0.001) and further weakly correlated to lag time, time to
peak, peak hight and velocity index (all p < 0.05).Prothrombotic markers and association with myocardial
injury
Statistically significant correlations were found be-
tween peak TnT and D-dimer and F1 + 2 (both p <
0.001) (Table 2). Linear trend analysis across quartiles
of peak TnT revealed increased levels of both markers
with increasing quartiles (p for trend < 0.001). When
adjusting for relevant covariates as visualized in Table 4a
both D-dimer and F1 + 2 remained significantly associ-
ated with peak TnT (both p < 0.001) (Table 4a and
Fig. 1a). Weak, but statistically significant correlations
were observed between TnT and ETP and velocity
index (Table 2).
Table 2 Correlations between prothrombotic markers and selected variables
D-dimer F1 + 2 ETP LT TTP pTG VT
Age r 0.412 0.277 −0.229 −0.075 −0.155 −0.086 0.088
p <0.001 <0.001 <0.001 0.021 <0.001 0.008 0.006
BMI r −0.184 −0.203 0.218 0.115 0.103 0.183 0.070
p <0.001 <0.001 <0.001 <0.001 0.001 <0.001 0.032
NT-ProBNP r 0.243 0.120 −0.118 0.072 0.003 −0.033 0.066
p <0.001 <0.001 0.002 0.026 0.92 0.30 0.044
HbA1c r 0.063 −0.015 0.033 0.025 0.006 0.055 0.048
p 0.141 0.765 0.161 0.44 0.85 0.09 0.146
Fasting glucose r 0.006 0.062 −0.054 0.042 −0.031 0.061 0.104
p 0.844 0.074 0.115 0.19 0.34 0.06 0.001
Peak TnT r 0.260 0.364 −0.072 −0.012 −0.059 0.001 0.065
p <0.001 <0.001 0.015 0.70 0.062 0.97 0.044
LVEF r −0.160 −0.090 0.022 −0.040 0.024 −0.065 −0.107
p <0.001 0.013 0.553 0.27 0.51 0.077 0.003
TnT Troponin T, LVEF left ventricular ejection fraction, BMI Body mass index, LT lag time, TTP Time to peak, pTG peak thrombin generation, VT Velocity index
r-values refer to Spearman’s rank correlation coefficient
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Significant correlations were found between D-dimer
and F1 + 2 and NT-ProBNP (both p = 0.001). Weak, but
statistically significant correlations were also observedFig. 1 D-dimer and F1 + 2 (medians) in quartiles of peak TnT (a) and NT-ProB
to blood sampling, CRP and NT-ProBNP; b * = adjusted for age, sex, BMI, hypefor the CAT-variables ETP, lagtime and velocity index
(Table 2). When dividing NT-ProBNP levels into quartiles
there were significant trends for increased levels of D-
dimer and F1 + 2 across quartiles (both p < 0.001). D-
dimer remained significantly associated with NT-proBNPNP (b). a * = adjusted for age, sex, BMI, hypertension, time from symptoms
rtension, time from symptoms to blood sampling and CRP
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0.001), whereas the association between NT-proBNP and
F1 + 2 was no longer statistically significant (p = 0.446)
(Table 4b, Fig. 1b).
A weak, but significant inverse correlation was found
between LVEF and D-dimer (p < 0.001), F1 + 2 (p =
0.013) and velocity index (p = 0.003) (Table 2). When di-
chotomizing LVEF levels at 40 % we observed signifi-
cantly higher levels of all variables (p < 0.001, p = 0.016
and p = 0.004, respectively) in patients with LVEF below
(n = 147), compared to above 40 % (Table 3). After ad-
justments for the covariates visualized in Table 4b the
difference in D-dimer levels remained statistically signifi-
cant (p = 0.003) whereas the association between LVEF
and F1 + 2 and velocity index was no longer significant
(p = 0.552 and p = 0.084, respectively).
Prothrombotic markers and traditional risk factors
Levels of D-dimer and F1 + 2 were significantly higher in
women (p < 0.001, both), while ETP was higher in men
(p = 0.001) (Table 3). There were no significant sex dif-
ferences in other CAT variables (data not shown).
No difference in any of the prothrombotic markers be-
tween smokers and non-smokers or patients with or
without previous CVD was observed.
In patients with hypertension, D-dimer, F1 + 2 and vel-
ocity index levels were significantly higher compared to
the group without hypertension (all p < 0.001), howeverTable 3 Levels of the prothrombotic markers according to group ch
n D-dim
Sex Male 800 424 (2
Female 187 609 (3
p 0.001
Smoking + 474 448 (2
- 513 467 (2
p 0.675
Previous CVD + 229 484 (2
- 758 452 (2
p 0.553
HT + 553 553 (3
- 418 418 (2
p 0.001
Diabetes + 870 454 (2
- 117 456 (2
p 0.285
LVEF (%) >40 147 440 (2
≤40 620 679 (4
p <0.001
Median (25,75 percentiles) values are given
HT hypertension, CVD cardiovascular disease, LVEF left ventricular ejection fractionthe association weakened after adjustments for covari-
ates (p = 0.018, p = 0.015 and p = 0.026, respectively).
Diabetic patients had significantly lower ETP levels
compared to non diabetics (p = 0.004) without any differ-
ences in other CAT variables (data not shown) or D-
dimer and F1 + 2. There were also limited correlations
between the haemostatic markers and HbA1c and fast-
ing glucose, except for velocity index which correlated
weakly to fasting glucose (Table 2).
Significant inverse correlations were observed between
BMI and D-dimer and F1 + 2 (both p < 0.001), whereas
all CAT variables were positively correlated with BMI
(all p < 0.05) (Table 2). There were significant trends for
decreased levels of D-dimer and F1 + 2 and increased ETP
across quartiles of BMI (adjusted p = 0.011, p = <0.001,
p < 0.001, respectively).
Discussion
In this large cohort of STEMI patients we found that
levels of D-dimer and F1 + 2 were significantly associ-
ated with the extent of myocardial injury as measured by
peak TnT. Significant associations between these coagu-
lation markers and myocardial function, assessed by
LVEF and NT-ProBNP, were further demonstrated.
We observed an inverse pattern for the in vivo throm-
bin generation and ex vivo potential to generate throm-
bin, which confirm previous findings in patients with
stable CAD [16]. It might be speculated that this is duearacteristics of the population
er (ng/mL) F1 + 2 (pmol/L) ETP (nM⋅min)
75,755) 238 (175,350) 1576 (1401,1748)
99,1008) 287 (203,395) 1494 (1284,1702)
0.001 0.001
75,796) 245 (179,347) 1573 (1364,1762)
95,795) 250 (178,382) 1557 (1368,1726)
0.594 0.269
86,798) 244 (177,332) 1569 (1348,1733)
86,796) 247 (180,369) 1563 (1370,1745)
0.386 0.503
55,952) 275 (197,398) 1563 (1366,1730)
73,773) 235 (174,346) 1565 (1366,1745)
0.001 0.381
46,848) 232 (169,324) 1490 (1261,1754)
92,795) 249 (180,365) 1572 (1373,1754)
0.142 0.004
85,755) 242 (174,363) 1573 (1371,1735)
08,1156) 297 (189,397) 1488 (1293,1691)
0.016 0.017
Table 4 Determinants of peak Troponin T (a) and NT-proBNP (b)
Determinants Standardized beta 95 % CIc p-value Determinants Standardized beta 95 % CI p-value
a)
D-dimer 0.138 <0.001– < 0.001 <0.001 F1 + 2 0.216 0.001–0.001 <0.001
Age −0.054 −0.012–0.002 0.156 Age −0.052 −0.012–0.002 0.157
Sex 0.025 −0.117–0.261 0.457 Sex 0.020 −0.128–0.244 0.542
BMI −0.026 −0.025–0.012 0.466 BMI −0.013 −0.22–0.015 0.706
HT −0.006 −0.179–0.152 0.870 HT −0.013 −0.194–0.132 0.710
Time framea −0.076 −0.018– − 0.001 0.032 Time framea −0.071 −0.017– < −0.001 0.042
CRPb 0.081 0.031–0.333 0.018 CRPb 0.083 0.039–0.335 0.013
NT-ProBNP 0.187 0.183–0.423 <0.001 NT-ProBNP 0.196 0.199–0.435 <0.001
b)
D-dimer 0.063 <−0.001– < 0.001 <0.001 F1 + 2 0.024 <−0.001– < 0.001 0.446
Age 0.180 0.011–0.023 0.050 Age 0.190 0.012–0.024 <0.001
Sex −0.083 −0.405– − 0.061 <0.001 Sex −0.085 −0.412– − 0.067 0.007
BMI −0.086 −0.039– − 0.006 0.008 BMI −0.087 −0.040– − 0.006 0.008
HT 0.125 0.145–0.445 <0.001 HT 0.126 0.148–0.449 <0.001
Time framea 0.307 0.031–0.046 <0.001 Time framea 0.307 0.031–0.046 <0.001
CRPb 0.035 −0.059–0.217 0.261 CRPb 0.043 −0.041–0.233 0.169
Multivariable regression analysis adjusted for age, sex, BMI, HT, Time frame, CRP and NT-proBNP
For abbreviations, see text
aTime from symptoms to blood sampling bLogtransformed c Confidence Intervals
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acute phase, resulting in reduced potential to generate
thrombin ex vivo, as an exhaustion phenomenon.
Patients with STEMI admitted to primary PCI, receive
heparin before or during the procedure. Heparin could
potentially influence the results. However, as heparin
was given only during the procedure, any effect on the
measured variables was most likely not present when the
blood samples were drawn 18 h (median time) after the
procedure.
There was a clear association between the variables
and myocardial necrosis measured by peak TnT. This
association was also present after adjustments for poten-
tial covariates including CRP. Thus the prothrombotic
state, to some degree also reflected in CAT parameters,
was probably not a result of inflammation in the acute
phase. We have previously reported similar results in an-
other AMI population [17]. In that particular study the
prothrombotic markers were measured 3–4 days after the
acute event, probably reflecting a more stable situation.
Nevertheless, the results clearly indicate that patients with
larger infarctions are in an increased hypercoagulable
state. It might therefore be discussed if patients with large
infarctions are sufficiently protected by use of double anti-
platelet therapy [18]. Use of warfarin has been shown to
reduce both D-dimer and F1 + 2 after AMI [19], and ran-
domized, clinical studies have shown beneficial effects on
clinical outcome by use of warfarin as anticoagulation
after acute MI [20, 21].The findings of a significant association between pro-
coagulant activity, shown especially by D-dimer and F1
+ 2, but also by CAT variables, and impaired myocardial
function in the acute phase of a STEMI, has to our
knowledge, not been reported before. Elevated pro-
thrombotic markers in the early phase of AMI are
known to identify patients with incrased risk of subse-
quent cardiac death, but such associations have so far
been reported to appear independent of LVEF [22]. Ele-
vated levels of D-dimer and F1 + 2 were shown along
with impaired myocardial function in another population
not suffering from CAD [23]. An association between el-
evated D-dimer and heart failure has also been demon-
strated [24]. Although there is no convincing evidence
that oral anticoagulant therapy reduces mortality and
vascular events in patients with heart failure and sinus
rhythm [25, 26], prolonged anticoagulant treatment of
such patients may be discussed after an AMI.
Diabetes is generally associated with elevated levels of
prothrombotic markers [27], also in diabetic patients
without coronary heart disease [28]. In our population,
diabetes and glucometabolic disturbances were limited
associated with a prothrombotic state, other than lower
levels of ETP and a significant correlation between fast-
ing glucose and velocity index. The latter may indicate
glucose per se to play a role for the propagation phase of
thrombin generation. Our results differ from some other
studies showing enhanced thrombin generation in dia-
betics [28–30]. However, in the study by Tripodi et al.
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in the presence of added thrombomodulin [29]. Differ-
ence in the populations investigated may also be of im-
portance. The limited findings in our study may be
explained by the elevated levels of prothrombotic
markers in the acute situation of an AMI, thus mask-
ing any difference. In addition, the levels of fasting glu-
cose and HbA1C indicate adequate treatment of
diabetes in the present population. Similar results have
also been shown in another study on stable patients
with CAD [16].
The inverse correlations between BMI and D-dimer
and F1 + 2 indicating a less hypercoagulable state in
overweight individuals, are in accordance with previous
findings in a population of stable CAD patients [16]
and is not easily explained. In contrast, all CAT vari-
ables were positively associated with BMI, indicative of
an increased potential to thrombin generation. Other
studies have shown positive correlation between BMI
and D-dimer, however, only in patients not diagnosed
with CVD [31]. In one study on healthy, obese individ-
uals D-dimer values were found not to be correlated to
BMI [32].
Increased levels of prothrombotic markers in patients
with hypertension is well known [33–35]. This was also
present in our population of STEMI patients when
evaluated in the acute phase, showing elevated levels of
D-dimer, F1 + 2 and velocity index in the group of
hypertensive patients, although highly dependent of re-
lated factors.
Limitations
Single bloodsampling prevented us from studying the
time-course of the measured markers. We are not sure
to have measured peak values of the variables or transi-
ent changes due to the variability in the time frame from
onset of symptoms to blood sampling. However, the re-
sults did not change when taken this into account in the
multivariate models. The blood samples were centri-
fuged at 4° C, thus any contact activation cannot be
ruled out. We have also not included an extra centrifu-
gation step before the analysis. The measure of LVEF by
echo cardiography was performed at different time
points from hospital discharge until 3 months after the
index infarct, and our cohort of STEMI patients was a
low risk population with few complications and just
slightly reduced LVEF, and this fact may have influenced
the results. As we do not have follow-up information of
this cohort, any impact of the results on future clinical
endpoints cannot be explored.
Conclusion
In our cohort of STEMI patients we could demonstrate
a significant association between levels of D-dimer andF1 + 2 and the extent of myocardial necrosis as assessed
by TnT. The high levels of these markers in patients
with low LVEF and high NT-ProBNP may indicate a hy-
percoagulable state in patients with impaired myocardial
function. The inverse relation between BMI and pro-
coagulant activity is not easily explainable, and has to be
further explored.
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